FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3166397110> ?p ?o ?g. }

• W3166397110 endingPage "5582" @default.
• W3166397110 startingPage "5582" @default.
• W3166397110 abstract "5582 Background: Uterine carcinosarcoma (UCS) is subtype of endometrial cancer (EC) with aggressive behavior and poor prognosis. UCS has not traditionally been included in EC clinical trials and treatment options are limited. Immune-oncology (IO) therapy has shown promise UCS, but it is unknown which patients benefit most. We sought to identify immunogenic markers in UCS and explore treatment response to IO therapy. Methods: Tumor samples were analyzed using Nex-Gen sequencing of the DNA (NextSeq, 592 genes or NovaSeq, whole exome sequencing) and RNA (NovaSeq, whole transcriptome sequencing) and immunohistochemistry (IHC) (Caris Life Sciences, Phoenix, AZ).PD-L1 IHC used SP-142 (cut-off >1%). MSI was tested by FA, IHC and NGS. TMB was measured by totaling somatic mutations per tumor (high > 10 mutations per MB). Immune cell fraction was calculated by QuantiSeq. Overall survival (OS) information was obtained from insurance claims data and Kaplan-Meier estimates were calculated for molecularly defined patient cohorts. Statistical significance was determined using chi-square and Wilcoxon rank sum test and p values adjusted for multiple comparisons (q) to be <0.05. Results: A total of 1,144 UCS tumors underwent comprehensive tumor profiling. 68.4% of samples were obtained from primary tumors and 31.6% from metastatic sites. 21.6% of tumors expressed PD-L1, 8.5% were TMB-H and 6.8% were MSI-H/MMRd. UCS patients treated with IO had longer median overall survival than those not treated with IO (months: 31.2 vs 19.4; HR(95% CI): 0.39 (0.17-0.76) p=0.005). Median OS was also increased for dMMR/MSI-H (OS not yet reached vs 18.9 months); HR(95% CI): 0.56 (0.36-0.92) p=0.019) and TMB-H (OS not yet reached vs 18.9 months); HR(95% CI): 0.62 (0.38-0.99) p=0.047). More patients are needed to determine if these markers predict response to IO therapy. The most common mutations in UCS led to pathway dysregulation in the PI3K, RAS, chromatin remodeling, HR, and WNT pathways. dMMR/MSI-H tumors have distinct molecular profiles compared to MSS tumors (table). Additionally, dMMR/MSI-H tumors had higher TMB (96.9% vs 2.2%, q<0.01) and increased frequency of PDL-1 (23.6% vs 13.8%; q=0.04). Immune checkpoint genes were more often expressed in MSI-H tumors, though this was non-significant except for IFNG (4.66-fold increase; q=0.01). Conclusions: IO therapy is associated with improved survival in USC. MSI and TMB are markers of improved OS in patients with UCS. MSI tumors have a distinct molecular profile compared to MSS tumors, and they appear to be more immunogenic, which could contribute to the improved survival seen in patients who received IO therapy.[Table: see text]" @default.
• W3166397110 created "2021-06-22" @default.
• W3166397110 creator A5003854163 @default.
• W3166397110 creator A5006628406 @default.
• W3166397110 creator A5008763534 @default.
• W3166397110 creator A5017383675 @default.
• W3166397110 creator A5018998777 @default.
• W3166397110 creator A5032881252 @default.
• W3166397110 creator A5039736511 @default.
• W3166397110 creator A5040325455 @default.
• W3166397110 creator A5042371948 @default.
• W3166397110 creator A5049762011 @default.
• W3166397110 creator A5054514509 @default.
• W3166397110 creator A5078849997 @default.
• W3166397110 creator A5080544645 @default.
• W3166397110 date "2021-05-20" @default.
• W3166397110 modified "2023-09-23" @default.
• W3166397110 title "Molecular determinants of response to immune-oncology therapy in uterine carcinosarcoma." @default.
• W3166397110 doi "https://doi.org/10.1200/jco.2021.39.15_suppl.5582" @default.
• W3166397110 hasPublicationYear "2021" @default.
• W3166397110 type Work @default.
• W3166397110 sameAs 3166397110 @default.
• W3166397110 citedByCount "0" @default.
• W3166397110 crossrefType "journal-article" @default.
• W3166397110 hasAuthorship W3166397110A5003854163 @default.
• W3166397110 hasAuthorship W3166397110A5006628406 @default.
• W3166397110 hasAuthorship W3166397110A5008763534 @default.
• W3166397110 hasAuthorship W3166397110A5017383675 @default.
• W3166397110 hasAuthorship W3166397110A5018998777 @default.
• W3166397110 hasAuthorship W3166397110A5032881252 @default.
• W3166397110 hasAuthorship W3166397110A5039736511 @default.
• W3166397110 hasAuthorship W3166397110A5040325455 @default.
• W3166397110 hasAuthorship W3166397110A5042371948 @default.
• W3166397110 hasAuthorship W3166397110A5049762011 @default.
• W3166397110 hasAuthorship W3166397110A5054514509 @default.
• W3166397110 hasAuthorship W3166397110A5078849997 @default.
• W3166397110 hasAuthorship W3166397110A5080544645 @default.
• W3166397110 hasConcept C104317684 @default.
• W3166397110 hasConcept C121608353 @default.
• W3166397110 hasConcept C126322002 @default.
• W3166397110 hasConcept C127716648 @default.
• W3166397110 hasConcept C143998085 @default.
• W3166397110 hasConcept C16671776 @default.
• W3166397110 hasConcept C204232928 @default.
• W3166397110 hasConcept C2777088508 @default.
• W3166397110 hasConcept C2777546739 @default.
• W3166397110 hasConcept C2778938455 @default.
• W3166397110 hasConcept C2781230642 @default.
• W3166397110 hasConcept C55493867 @default.
• W3166397110 hasConcept C71924100 @default.
• W3166397110 hasConcept C86803240 @default.
• W3166397110 hasConceptScore W3166397110C104317684 @default.
• W3166397110 hasConceptScore W3166397110C121608353 @default.
• W3166397110 hasConceptScore W3166397110C126322002 @default.
• W3166397110 hasConceptScore W3166397110C127716648 @default.
• W3166397110 hasConceptScore W3166397110C143998085 @default.
• W3166397110 hasConceptScore W3166397110C16671776 @default.
• W3166397110 hasConceptScore W3166397110C204232928 @default.
• W3166397110 hasConceptScore W3166397110C2777088508 @default.
• W3166397110 hasConceptScore W3166397110C2777546739 @default.
• W3166397110 hasConceptScore W3166397110C2778938455 @default.
• W3166397110 hasConceptScore W3166397110C2781230642 @default.
• W3166397110 hasConceptScore W3166397110C55493867 @default.
• W3166397110 hasConceptScore W3166397110C71924100 @default.
• W3166397110 hasConceptScore W3166397110C86803240 @default.
• W3166397110 hasIssue "15_suppl" @default.
• W3166397110 hasLocation W31663971101 @default.
• W3166397110 hasOpenAccess W3166397110 @default.
• W3166397110 hasPrimaryLocation W31663971101 @default.
• W3166397110 hasRelatedWork W2007895704 @default.
• W3166397110 hasRelatedWork W2017292316 @default.
• W3166397110 hasRelatedWork W2058595915 @default.
• W3166397110 hasRelatedWork W2788838846 @default.
• W3166397110 hasRelatedWork W3027015150 @default.
• W3166397110 hasRelatedWork W3094370183 @default.
• W3166397110 hasRelatedWork W3128010851 @default.
• W3166397110 hasRelatedWork W3209525175 @default.
• W3166397110 hasRelatedWork W4295227120 @default.
• W3166397110 hasRelatedWork W4320155982 @default.
• W3166397110 hasVolume "39" @default.
• W3166397110 isParatext "false" @default.
• W3166397110 isRetracted "false" @default.
• W3166397110 magId "3166397110" @default.
• W3166397110 workType "article" @default.